Physician profile
Beverly A Schaefer
NPI 1699091272
$119,746.39
in general payments reported to CMS, 2019-2025
17 companies · $16K in 2025
The $16K reported for 2025 was more than what 89% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $1,780 · 2021: $637 · 2022: $8,314 · 2023: $68K · 2024: $25K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Consulting Fee: $25K · Travel and Lodging: $13K · Honoraria: $7,900 · Food and Beverage: $2,447 · Education: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,200.00 |
| Consulting Fee | $24,939.00 |
| Travel and Lodging | $12,841.38 |
| Honoraria | $7,900.00 |
| Food and Beverage | $2,447.18 |
| Education | $461.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $86,283.36 | 2022-2025 | Hemgenix, Idelvion |
| Octapharma USA, INC. | $17,019.07 | 2019-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Nuwiq, Fibryga & Balfaxar |
| Genzyme Corporation | $7,163.90 | 2023-2025 | |
| Hema Biologics, LLC | $6,031.47 | 2022-2023 | Sevenfact |
| Genentech USA, INC. | $1,746.71 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,024.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $130.87 | 2019 | |
| Novo Nordisk INC | $101.44 | 2019-2025 | |
| Genentech, INC. | $57.46 | 2023-2025 | Hemlibra |
| Takeda Pharmaceuticals U.S.A., INC. | $39.93 | 2020-2022 | |
| Shire North American Group INC | $24.69 | 2019 | |
| Syndax Pharmaceuticals, INC. | $24.16 | 2025 | Revuforj |
| Kedrion Biopharma, INC. | $22.69 | 2025 | Gammaked, Koate, Albuked |
| Biomarin Pharmaceutical INC. | $21.89 | 2023 | |
| Sanofi-Aventis U.S. LLC | $21.15 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.90 | 2021 | |
| Pfizer INC. | $16.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.